Page 91 - Read Online
P. 91

Page 6 of 7                                                    McNamee. J Transl Genet Genom 2018;2:20. I  https://doi.org/10.20517/jtgg.2018.24





















               Figure 1. The UK Pharmacogenetics and Stratified Medicine Network. The network was set up in the UK to develop multidisciplinary
               collaborations, across academic, industrial, healthcare and regulatory sectors, to encourage research in personalized medicine and
               promote the use of pharmacogenetics in the clinic to improve patient healthcare outcomes http://www.uk-pgx-stratmed.co.uk


               DECLARATIONS
               Authors’ contributions
               The author contributed solely to the article.

               Availability of data and materials
               Not applicable.

               Financial support and sponsorship
               None.

               Conflicts of interest
               All authors declared that there are no conflicts of interest.

               Ethical approval and consent to participate
               Not applicable.

               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2018.


               REFERENCES
               1.   Parkes M. Personalised medicine and genetic prediction--are we there yet? Clin Med (Lond) 2013;13:s62-4.
               2.   Singh S. Stratified medicine: maximizing clinical benefit by biomarker-driven health care. Nestle Nutr Inst Workshop 2016;84:91-102.
               3.   Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol 2011;8:184-7.
               4.   Hamann U. Hereditary breast cancer: high-risk genes, genetic testing and clinical implications. Clin Lab 2000;46:447-61.
               5.   Bell J. Life sciences industrial strategy. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach-
                   ment_data/file/650447/LifeSciencesIndustrialStrategy_acc2.pdf. [Last accessed on 1 Nov 2018]
               6.   Brittain HK, Scott R, Thomas E. The rise of the genome and personalised medicine. Clin Med (Lond) 2017;17:545-51.
               7.   Patel JN, Wiebe LA, Dunnenberger HM, McLeod HL. Value of supportive care pharmacogenomics in oncology practice. Oncologist
                   2018;23:956-64.
               8.   FDA. Table of pharmacogenomic biomarkers in drug labeling. Available from: https://www.fda.gov/Drugs/ScienceResearch/ucm572698.
                   htm. [Last accessed on 1 Nov 2018]
               9.   Zhao X, Modur V, Carayannopoulos LN, Laterza OF. Biomarkers in pharmaceutical research. Clin Chem 2015;61:1343-53.
   86   87   88   89   90   91   92   93   94   95   96